UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335. Amgen reported in-line topline sales for Q3, with most products as ...

Amgen (NASDAQ:AMGN – Free Report) had its target price cut by UBS Group from $335.00 to $326.00 in a report released on Thursday, Benzinga reports. They currently have a neutral rating on the medical ...

Amgen (NASDAQ:AMGN – Get Free Report) will be releasing its earnings data before the market opens on Wednesday, October 30th.

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Amgen Inc.'s Q3 earnings may not be a major upside, but new pipeline drugs and potential breakthroughs could drive growth.

* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share. (a) The adjustments primarily include noncash amortization of intangible assets ...

Amgen AMGN reported third-quarter 2024 adjusted earnings of $5.58 per share, which beat the Zacks Consensus Estimate of $5.11 ...

The new price target represents a valuation ... This forecast is based on the performance of several of Amgen's key franchises, including Enbrel, Nplate, Repatha, Otezla, Mvasi, Tezspire, and ...

UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335 ... offset by higher Nplate, Blincyto, and Repatha sales, the analyst tells investors in a research note.

Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN ... partially offset by 2% lower net selling price. Excluding sales from our Horizon Therapeutics (Horizon) acquisition, product sales grew ...